Program
recombinant FVIIa
Also written as “activated recombinant human factor VII”, “eptacog alfa (activated)” and “Coagulation Factor VIIa (Recombinant)”.
Its studies are mostly in Hemophilia A · Cerebral Hemorrhage · Wounds and Injuries · Fibrosis · Postpartum Hemorrhage, led by 4 companies.
Drug pageRecombinant FVIIa: every studyAll 58 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 361 open or running | phase 4since Dec 11, 2007 | Jan 19, 2005 | Aug 26, 2027phase 4 · NCT07157423 |
| Laboratoire français de Fractionnement et de Biotechnologiesits history only | 20 open or running | phase 3since Sep 9, 2015 | Sep 9, 2015 | none ahead |
| rEVO Biologicsits history only | 20 open or running | phase 3since Dec 18, 2013 | Oct 15, 2012 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Mar 4, 2017 | Mar 4, 2017 | none ahead |
Also a collaborator on its studies: LFB USA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novo Nordisk only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Jan 19, 2005.
- Dec 14, 2005Phase 2 study in Cerebral HemorrhageNCT00266006 · 90 enrolled · Japan
- May 8, 2006Phase 3 study in Wounds and InjuriesNCT00323570 · United States
- Jan 24, 2007Phase 2 study in Cerebral HemorrhageNCT00426803 · 400 enrolled · Australia, Austria, Belgium and more
- Jun 13, 2007Phase 2 study in Hemophilia ANCT00486278 · 51 enrolled · United States, Argentina, Brazil and more
- Dec 11, 2007Phase 4 study in Congenital Bleeding DisorderNCT00571584 · 24 enrolled · France, Hungary, Israel and more
- Jul 8, 2011Phase 3 study in Congenital Bleeding DisorderNCT01392547 · 72 enrolled · United States, Austria, Brazil and more
- Mar 21, 20127 phase 1 studiesNCT01562457, NCT01561950, NCT01561937 and 4 more
- Mar 21, 2012Phase 4 study in Congenital Bleeding DisorderNCT01561391 · 36 enrolled · United States
- Mar 21, 20128 phase 2 studiesNCT01561352, NCT01563458, NCT01562821 and 5 more
- Mar 22, 2012Phase 3 study in Acquired Bleeding DisorderNCT01562574 · 82 enrolled · Australia
- May 14, 20122 phase 2 studiesNCT01601613, NCT01601457
- Sep 13, 2013Phase 1 study in Hemophilia ANCT01949792 · 6 enrolled · Spain
- Jan 28, 2014Phase 1 study in Hemophilia ANCT02084810
- Aug 19, 2025Phase 4 study in Postpartum HemorrhageNCT07157423 · 64 planned · India
Ahead
- Aug 26, 2027Primary completion: phase 4 study in Postpartum HemorrhageNCT07157423
TargetBeta
“A recombinant form of the vitamin K-dependent glycoprotein and coagulation factor VIIa (FVIIa), that can be used for the treatment of bleeding episodes and perioperative management in patients with hemophilia, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia”NCIt, by rule
Studies
All 36 Novo Nordisk leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07157423Postpartum Hemorrhage · India | 4 | Recruiting | Aug 26, 2027 | 64 |
| NCT02084810Hemophilia A | 1 | Withdrawn | Jul 2014 | 0 |
| NCT01949792Hemophilia A · Spain | 1 | Completed | Nov 2013 | 6 |
| NCT01601457Wounds and Injuries · United Kingdom | 2 | Completed | Apr 2004 | 48 |
| NCT01601613Dengue · Malaysia, Philippines, Thailand | 2 | Completed | Nov 2002 | 28 |
| NCT01566786Cerebral Hemorrhage · Australia, Denmark, Finland and more | 2 | Completed | Oct 2002 | 48 |
| NCT01564563Acquired Bleeding Disorder · United States | 2 | Terminated | Oct 27, 2003 | 11 |
| NCT01563523Wounds and Injuries · Australia, Austria, Canada and more | 2 | Completed | Oct 2003 | 283 |
| NCT01563471Congenital Bleeding Disorder · France | 1 | Completed | Jul 2002 | 39 |
| NCT01563445Cerebral Hemorrhage · United States | 2 | Completed | Mar 2003 | 40 |
| NCT01563458Acquired Bleeding Disorder · Australia, Canada, France and more | 2 | Completed | Aug 2003 | 208 |
| NCT01562821Fibrosis · China, Taiwan, Thailand | 2 | Completed | Dec 2002 | 235 |
| NCT01562587Hemophilia A · Germany, Greece, Italy and more | 1 | Completed | May 2003 | 18 |
| NCT01562574Acquired Bleeding Disorder · Australia | 3 | Completed | Aug 2004 | 82 |
| NCT01562158Acquired Bleeding Disorder · United States, Australia, Austria and more | 2 | Completed | Oct 2003 | 100 |
| NCT01562457Hemophilia A · France, Germany, Israel | 1 | Completed | Apr 2006 | 30 |
| NCT01561950Haemostasis · United States | 1 | Terminated | Jan 2009 | 91 |
| NCT01561937Haemostasis · United States | 1 | Completed | Jul 2008 | 127 |
| NCT01561924Congenital Bleeding Disorder · United States, Denmark, France and more | 1 | Completed | May 2006 | 17 |
| NCT01561417Thrombasthenia · France | 1 | Completed | Sep 2006 | 28 |
| NCT01561391Congenital Bleeding Disorder · United States | 4 | Completed | May 2004 | 36 |
| NCT01561352Cystitis, Hemorrhagic · United States | 2 | Completed | Nov 2003 | 7 |
| NCT01392547Congenital Bleeding Disorder · United States, Austria, Brazil and more | 3 | Completed | Aug 2012 | 72 |
| NCT00571584Congenital Bleeding Disorder · France, Hungary, Israel and more | 4 | Completed | Mar 2004 | 24 |
| NCT00486278Hemophilia A · United States, Argentina, Brazil and more | 2 | Completed | Jun 2010 | 51 |
| NCT00426803Cerebral Hemorrhage · Australia, Austria, Belgium and more | 2 | Completed | Jun 2004 | 400 |
| NCT00323570Wounds and Injuries · United States | 3 | Withdrawn | Jun 2007 | 0 |
| NCT00266006Cerebral Hemorrhage · Japan | 2 | Completed | Apr 2007 | 90 |
| NCT00184548Wounds and Injuries · United States, Brazil, Czech Republic and more | 3 | Terminated | Sep 2008 | 554 |
| NCT00154492Fibrosis · Austria, Czech Republic, Denmark and more | 2 | Completed | Aug 2006 | 265 |
| NCT00154427Acquired Bleeding Disorder · United States, Argentina, Brazil and more | 2 | Terminated | Nov 2007 | 172 |
| NCT00127283Cerebral Hemorrhage · United States, Australia, Austria and more | 3 | Completed | Jan 2007 | 829 |
| NCT00123591Wounds and Injuries · Canada, Finland, Germany and more | 2 | Completed | May 2006 | 96 |
| NCT00108758Congenital Bleeding Disorder · United States, Argentina, Brazil and more | 2 | Completed | Nov 2005 | 23 |
| NCT00104455Congenital Bleeding Disorder · United States | 1 | Completed | Nov 2004 | 64 |
| NCT00102037Acquired Bleeding Disorder · United States | 2 | Completed | Feb 2006 | 50 |
How it is read
Names in the registry
- “activated recombinant human factor VII”, 32 entries
- “eptacog alfa (activated)”, 12 entries
- “Coagulation Factor VIIa (Recombinant)”, 3 entries
- “Eptacog alfa (NovoSeven)”, 1 entry
- “Eptacog alfa, biosimilar”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 15 studies
- Cerebral Hemorrhage, 5 studies
- Wounds and Injuries, 5 studies
- Fibrosis, 2 studies
- Postpartum Hemorrhage, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.